Abstract
The invention relates to use of specific peptides derived from the cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. The invention further relates to compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
| Original language | American English |
|---|---|
| Patent number | EP2828291 |
| IPC | C07K 14/ 705 A I |
| Priority date | 14/03/13 |
| State | Published - 28 Jan 2015 |
Fingerprint
Dive into the research topics of 'PEPTIDES DERIVED FROM THE D1-DOMAIN OF NKP46'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver